Ipsen Secures Ex-US Rights to Day One’s Pediatric Cancer Medication with $111M Upfront Investment

1. Deal Details: Ipsen has secured the ex-US rights to Day One's pediatric cancer medication, tovorafenib, with a $111 million upfront investment, including $40 million in cash and $71 million in equity.
2. Global Rights: Ipsen gains global rights to the medication, excluding the US, for the treatment of pediatric glioma.
3. Therapy: The medication, Ojemda, is a therapy for pediatric glioma, the most common childhood brain tumor.
4. Partnership: The deal marks an exclusive ex-US licensing agreement between Ipsen and Day One to commercialize tovorafenib.
5. Financial Terms: The total deal value is $461 million, with the upfront payment of $111 million and additional milestones and royalties.